

Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045

April 2018

Supply Interruption Update of The Spinal Ampul Product Line

Dear Valued Customer,

This letter is to update you on a supply interruption involving our spinal ampul product line so that appropriate contingency plans can be made to help facilitate patient care. Due to capacity constraints and delayed release timing at the manufacturing plant, the bupivacaine spinal and Marcaine™ spinal presentations below are currently out of stock with full recovery dates in Q2 2018 and Q3 2018.

Please be aware that Pfizer Marcaine™ spinal ampuls are also sold to kit-packers for inclusion in anesthesia trays. Spinal ampuls may be unavailable in trays while backorders continue. Spinal ampuls may continue to be unavailable in trays for a period of time after the dates listed below.

In addition, reformulation activities are ongoing on the lidocaine spinal ampuls below. We expect reformulation activities to complete and production to resume in 2018, leading to a next delivery in January 2019.

A significant amount of bupivacaine spinal product was released at the plant in mid April and will clear wholesaler and other trading partner backorders placed through April 12th. Shipments to wholesalers and other trading partners will occur by late April. A subsequent delivery of bupivacaine spinal product is expected in late May. Additionally, Marcaine spinal product was released at the plant in late March, enough to clear approximately 80% of backorders through March 23rd.

Pfizer Injectables recognizes the importance of these drugs and is making every effort to restock the market. The product and supply detail is listed in the table below.

Unit of Sale NDC	Description	Next Delivery	Estimated Recovery
00409-3613-01	Bupivacaine Spinal 0.75% (bupivacaine in dextrose injection, USP) 15 mg/2 mL (7.5 mg/mL) Glass Ampul	Late April	June
00409-1761-02	Marcaine™ Spinal 0.75% (bupivacaine hydrochloride in dextrose injection, USP) 15 mg/2 mL (7.5 mg/mL) Glass Ampul	July	September
00409-4712-01	Lidocaine Hydrochloride and 7.5% Dextrose Injection, USP (For Spinal Anesthesia) 100 mg/2 mL (50 mg/mL) Glass Ampul	January 2019	March 2019

Pfizer Injectables is committed to keeping you informed on supply interruptions and will continue to provide updates on this supply situation as new information becomes available. Please reach out to your Pfizer Sales Representative or Executive if you have any questions.

Thank you,

Stephen Colvill
Anesthesia Portfolio Marketing Manager